Effect of the Combination of Hemodialysis and Hemoperfusion on Clearing Advanced Glycation End Products: A Prospective, Randomized, Two-Stage Crossover Trial in Patients under Maintenance Hemodialysis

Blood Purification

Volumn 40, Issue 2, 2015, Pages 127-132

  Zhang, Yu ^a   Mei, Chang Lin ^b   Rong, Shu ^b   Liu, Yuan Yuan ^a   Xiao, Guan Qing ^a   Shao, Yong Hong ^a   Kong, Yao Zhong ^a  

^a First People's Foshan Hospital   (China)

^b SECOND MILITARY MEDICAL UNIVERSITY   (China)

Author keywords

Advanced glycation end products; Hemodialysis; Hemoperfusion

Indexed keywords

ADVANCED GLYCATION END PRODUCT; ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; C REACTIVE PROTEIN; COMPLEMENT COMPONENT C3; COMPLEMENT COMPONENT C4; INTERLEUKIN 6; TUMOR NECROSIS FACTOR ALPHA; UREMIC TOXIN;

ADULT; ANEMIA; ARTICLE; BLOOD SAMPLING; CARDIOVASCULAR DISEASE; CHRONIC GLOMERULONEPHRITIS; CLINICAL ARTICLE; COMPARATIVE STUDY; CONTROLLED STUDY; CROSSOVER PROCEDURE; DIABETIC NEPHROPATHY; FEMALE; HEMODIALYSIS; HEMODIALYSIS MACHINE; HEMODIALYSIS PATIENT; HEMOPERFUSION; HUMAN; HYPERTENSION; KIDNEY DISEASE; KIDNEY POLYCYSTIC DISEASE; MAINTENANCE THERAPY; MALE; MIDDLE AGED; PRIORITY JOURNAL; PROSPECTIVE STUDY; QUALITY CONTROL; RANDOMIZED CONTROLLED TRIAL; TREATMENT DURATION; AGED; BLOOD; KIDNEY FAILURE, CHRONIC; MULTIMODALITY CANCER THERAPY; PATHOLOGY; RENAL REPLACEMENT THERAPY; UREMIA;

ADULT; AGED; COMBINED MODALITY THERAPY; CROSS-OVER STUDIES; FEMALE; GLYCOSYLATION END PRODUCTS, ADVANCED; HEMOPERFUSION; HUMANS; KIDNEY FAILURE, CHRONIC; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; RENAL DIALYSIS; TUMOR NECROSIS FACTOR-ALPHA; UREMIA;

EID: 84936938873     PISSN: 02535068     EISSN: 14219735     Source Type: Journal    
DOI: 10.1159/000376604     Document Type: Article

References (24)

1. Go AS, Chertow GM, Fan D, McCulloch CE, Hsu CY: Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization. N Engl J Med 2004; 351: 1296-1305.
2. Wright J, Hutchison A: Cardiovascular disease in patients with chronic kidney disease. Vasc Health Risk Manag 2009; 5: 713-722.
3. London GM, Marty C, Marchais SJ, Guerin AP, Metivier F, de Vernejoul MC: Arterial calcifications and bone histomorphometry in end-stage renal disease. J Am Soc Nephrol 2004; 15: 1943-1951.
4. Furuya R, Kumagai H, Miyata T, Fukasawa H, Isobe S, Kinoshita N, Hishida A: High plasma pentosidine level is accompanied with cardiovascular events in hemodialysis patients. Clin Exp Nephrol 2012; 16: 421-426.
5. Hojs R, Bevc S, Ekart R: Biomarkers in hemodialysis patients. Adv Clin Chem 2012; 57: 29-56.
6. Nin JW, Jorsal A, Ferreira I, Schalkwijk CG, Prins MH, Parving HH, Tarnow L, Rossing P, Stehouwer CD: Higher plasma levels of advanced glycation end products are associated with incident cardiovascular disease and allcause mortality in type 1 diabetes: A 12-year follow-up study. Diabetes Care 2011; 34: 442-447.
7. Kiuchi K, Nejima J, Takano T, Ohta M, Hashimoto H: Increased serum concentrations of advanced glycation end products: A marker of coronary artery disease activity in type 2 diabetic patients. Heart 2001; 85: 87-91.
8. Kratochvilova M, Zakiyanov O, Kalousova M, Kriha V, Zima T, Tesar V: Associations of serum levels of advanced glycation end products with nutrition markers and anemia in patients with chronic kidney disease. Ren Fail 2011; 33: 131-137.
9. Gerdemann A, Wagner Z, Solf A, Bahner U, Heidland A, Vienken J, Schinzel R: Plasma levels of advanced glycation end products during haemodialysis, haemodiafiltration and haemofiltration: potential importance of dialysate quality. Nephrol Dial Transplant 2002; 17: 1045-1049.
10. Mandolfo S, Borlandelli S, Imbasciati E: Leptin and beta2-microglobulin kinetics with three different dialysis modalities. Int J Artif Organs 2006; 29: 949-955.
11. Makita Z, Radoff S, Rayfield EJ, Yang Z, Skolnik E, Delaney V, Friedman EA, Cerami A, Vlassara H: Advanced glycosylation end products in patients with diabetic nephropathy. N Engl J Med 1991; 325: 836-842.
12. Nin JW, Jorsal A, Ferreira I, Schalkwijk CG, Prins MH, Parving HH, Tarnow L, Rossing P, Stehouwer CD: Higher plasma soluble receptor for advanced glycation end products (sRAGE) levels are associated with incident cardiovascular disease and all-cause mortality in type 1 diabetes: A 12-year follow-up study. Diabetes 2010; 59: 2027-2032.
13. Liabeuf S, Drueke TB, Massy ZA: Proteinbound uremic toxins: new insight from clinical studies. Toxins (Basel) 2011; 3: 911-919.
14. Kalousova M, Zima T, Tesar V, Lachmanova J: Advanced glycation end products and advanced oxidation protein products in hemodialyzed patients. Blood Purif 2002; 20: 531-536.
15. Meert N, Eloot S, Waterloos MA, Van Landschoot M, Dhondt A, Glorieux G, Ledebo I, Vanholder R: Effective removal of proteinbound uraemic solutes by different convective strategies: A prospective trial. Nephrol Dial Transplant 2009; 24: 562-570.
16. Meerwaldt R, Zeebregts CJ, Navis G, Hillebrands JL, Lefrandt JD, Smit AJ: Accumulation of advanced glycation end products and chronic complications in ESRD treated by dialysis. Am J Kidney Dis 2009; 53: 138-150.
17. Slowik-Zylka D, Safranow K, Dziedziejko V, Ciechanowski K, Dziewanowski K, Chlubek D: The effect of dialysis membrane type on plasma concentrations of pentosidine, a marker of carbonyl stress, in hemodialyzed patients. Pol Arch Med Wewn 2009; 119: 614-620.
18. Vaslaki L, Major L, Berta K, Karatson A, Misz M, Pethoe F, Ladanyi E, Fodor B, Stein G, Pischetsrieder M, Zima T, Wojke R, Gauly A, Passlick-Deetjen J: On-line haemodiafiltration versus haemodialysis: stable haematocrit with less erythropoietin and improvement of other relevant blood parameters. Blood Purif 2006; 24: 163-173.
19. Gil HW, Kim SJ, Yang JO, Lee EY, Hong SY: Clinical outcome of hemoperfusion in poisoned patients. Blood Purif 2010; 30: 84-88.
20. Davankov V, Pavlova L, Tsyurupa M, Brady J, Balsamo M, Yousha E: Polymeric adsorbent for removing toxic proteins from blood of patients with kidney failure. J Chromatogr B Biomed Sci Appl 2000; 739: 73-80.
21. Alcorn JF, van der Velden J, Brown AL, McElhinney B, Irvin CG, Janssen-Heininger YM: C-Jun N-terminal kinase 1 is required for the development of pulmonary fibrosis. Am J Respir Cell Mol Biol 2009; 40: 422-432.
22. Chen SJ, Jiang GR, Shan JP, Lu W, Huang HD, Ji G, Wu P, Wu GF, Wang W, Zhu C, Bian F: Combination of maintenance hemodialysis with hemoperfusion: A safe and effective model of artificial kidney. Int J Artif Organs 2011; 34: 339-347.
23. Holubek WJ, Hoffman RS, Goldfarb DS, Nelson LS: Use of hemodialysis and hemoperfusion in poisoned patients. Kidney Int 2008; 74: 1327-1334.
24. Shalkham AS, Kirrane BM, Hoffman RS, Goldfarb DS, Nelson LS: The availability and use of charcoal hemoperfusion in the treatment of poisoned patients. Am J Kidney Dis 2006; 48: 239-241.